Tislelizumab NSCLC Inclusion Recommended for Du...

By HEOR Staff Writer

February 9, 2026

Tislelizumab NSCLC Inclusion in Dutch Basic Package Zorginstituut Nederland's Tislelizumab NSCLC Inclusion Recommendation Zorginstituut Nederland's advis...
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
Johnson & Johnson’s Medicine Access Agreement: Paving the Way for ...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Driving Economic Transformation through Brain Health Investment in Africa
NICE Endorses Natalizumab RRMS Treatment Expansion for Refractory Cases